Kymera Therapeutics Inc (KYMR)

Feb 21, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Feb 21, 2025

Feb 20, 2025

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27 - The Manila Times

Feb 20, 2025

Feb 20, 2025

Kymera Therapeutics (KYMR) Expected to Announce Earnings on Thursday - MarketBeat

Feb 20, 2025

Feb 19, 2025

Kymera Therapeutics: Plenty Of Potential, But A Long Way From The Finish Line (KYMR) - Seeking Alpha

Feb 19, 2025

Feb 18, 2025

When the Price of (KYMR) Talks, People Listen - Stock Traders Daily

Feb 18, 2025

Feb 17, 2025

Getting In Cheap On Kymera Therapeutics, Inc. (NASDAQ:KYMR) Is Unlikely - Simply Wall St

Feb 17, 2025

Feb 17, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Feb 17, 2025

Feb 14, 2025

Kymera rises after presentation at the J.P. Morgan event - MSN

Feb 14, 2025

Feb 09, 2025

SG Americas Securities LLC Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

Feb 09, 2025

Feb 08, 2025

Jennison Associates LLC Trims Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

Feb 08, 2025

Feb 08, 2025

Head to Head Review: Kymera Therapeutics (NASDAQ:KYMR) & Gene Biotherapeutics (OTCMKTS:CRXM) - Defense World

Feb 08, 2025

Feb 07, 2025

Financial Snapshot: Analyzing Kymera Therapeutics Inc (KYMR)’s Key Ratio Metrics - The Dwinnex

Feb 07, 2025

Feb 07, 2025

Long Term Trading Analysis for (KYMR) - Stock Traders Daily

Feb 07, 2025

Feb 05, 2025

SG Americas Securities LLC Cuts Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Feb 05, 2025

Feb 04, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Feb 04, 2025

Jan 30, 2025

Kymera Therapeutics to Participate in Upcoming February Investor Conferences - The Manila Times

Jan 30, 2025

Jan 30, 2025

Inside Kymera's Upcoming Biotech Presentations: Key Investor Events You Can't Miss - StockTitan

Jan 30, 2025

Jan 26, 2025

(KYMR) Technical Data - Stock Traders Daily

Jan 26, 2025

Jan 26, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $55.06 Average PT from Brokerages - Defense World

Jan 26, 2025

Jan 23, 2025

Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $55.06 - MarketBeat

Jan 23, 2025

Jan 21, 2025

Kymera Therapeutics (NASDAQ:KYMR) Earns "Overweight" Rating from Stephens - MarketBeat

Jan 21, 2025

Jan 21, 2025

Kymera announces expansion of KT-474 HS and AD phase 2 studies - MSN

Jan 21, 2025

Jan 17, 2025

Kymera Therapeutics soars as Sanofi expands phase 2 trials - MSN

Jan 17, 2025

Jan 17, 2025

Kymera Therapeutics (NASDAQ:KYMR) Trading Down 6.3%Time to Sell? - MarketBeat

Jan 17, 2025

Jan 17, 2025

Kymera Therapeutics (NASDAQ:KYMR) Provides Business Update and Preliminary Cash Balance for 2024 - Defense World

Jan 17, 2025

Jan 16, 2025

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last? - MSN

Jan 16, 2025

Jan 16, 2025

Kymera Therapeutics describes IRAK-4 degraders - BioWorld Online

Jan 16, 2025

Jan 16, 2025

How the (KYMR) price action is used to our Advantage - Stock Traders Daily

Jan 16, 2025

Jan 16, 2025

JPMorgan Chase & Co. Acquires 95,547 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Jan 16, 2025

Jan 15, 2025

Kymera Provides Pipeline Objectives for 2025, Stock Gains - MSN

Jan 15, 2025

Jan 14, 2025

Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutio - GuruFocus.com

Jan 14, 2025

Jan 14, 2025

Kymera stock surges on product pipeline update By Investing.com - Investing.com Canada

Jan 14, 2025

Jan 14, 2025

Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments - Yahoo Finance

Jan 14, 2025

Jan 14, 2025

Kymera Therapeutics (NASDAQ:KYMR) Trading 6.4% HigherHere's Why - MarketBeat

Jan 14, 2025

Jan 14, 2025

Kymera reports progress in immunology drug trials By Investing.com - Investing.com South Africa

Jan 14, 2025

Jan 14, 2025

Kymera Therapeutics Shares Surge Amid 2025 Strategy Unveil - TipRanks

Jan 14, 2025

Jan 14, 2025

Kymera reports progress in immunology drug trials - Investing.com India

Jan 14, 2025

Jan 14, 2025

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - The Manila Times

Jan 14, 2025

Jan 14, 2025

Kymera Unveils Ambitious 2025 Immunology Pipeline Plans with $850M Cash Runway - StockTitan

Jan 14, 2025

Jan 09, 2025

Analysts Set Expectations for KYMR FY2029 Earnings - Defense World

Jan 09, 2025

Jan 08, 2025

Stifel sustains Buy on Kymera stock amid TPD drug optimism By Investing.com - Investing.com UK

Jan 08, 2025

Jan 08, 2025

Equities Analysts Set Expectations for KYMR FY2029 Earnings - MarketBeat

Jan 08, 2025

Jan 07, 2025

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14 - The Manila Times

Jan 07, 2025

Jan 07, 2025

Kymera Therapeutics to Present Strategic Roadmap at J.P. Morgan Healthcare Conference - StockTitan

Jan 07, 2025

Jan 06, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Sells $130,635.75 in Stock - MarketBeat

Jan 06, 2025

Jan 05, 2025

(KYMR) Trading Report - Stock Traders Daily

Jan 05, 2025

Jan 02, 2025

STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space - BioWorld Online

Jan 02, 2025